Public-registry site landscape for NCT07700979, a Gastric / Gastroesophageal Junction Adenocarcinoma study sponsored by Akeso. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07700979 (registry record) |
| Sponsor | Akeso |
| Condition(s) | Gastric / Gastroesophageal Junction Adenocarcinoma |
| Phase | PHASE3 |
| Listed sites | 25 |
| Site countries | United States, China, Germany, Poland |
At Mayo Clinic — one of the facilities listed on this trial — 9 other studies are actively recruiting Gastric / Gastroesophageal Junction Adenocarcinoma patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07700979 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →